Lai, A. Y., Sorrentino, J. A., Dragnev, K. H., Weiss, J. M., Owonikoko, T. K., Rytlewski, J. A., . . . Roberts, P. J. (2020). CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer.
শিকাগো স্টাইলে সাইটেশনLai, Anne Y., et al. "CDK4/6 Inhibition Enhances Antitumor Efficacy of Chemotherapy and Immune Checkpoint Inhibitor Combinations in Preclinical Models and Enhances T-cell Activation in Patients With SCLC Receiving Chemotherapy." J Immunother Cancer 2020.
এমএলএ সাইটেশনLai, Anne Y., et al. "CDK4/6 Inhibition Enhances Antitumor Efficacy of Chemotherapy and Immune Checkpoint Inhibitor Combinations in Preclinical Models and Enhances T-cell Activation in Patients With SCLC Receiving Chemotherapy." J Immunother Cancer 2020.